A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4173-4182

  Hong, David S ^a   Bowles, Daniel W ^b   Falchook, Gerald S ^a   Messersmith, Wells A ^b   George, Goldy C ^a   O'Bryant, Cindy L ^b   Vo, Alex C H ^c   Klucher, Kevin ^c   Herbst, Roy S ^a   Eckhardt, S Gail ^b   Peterson, Scott ^c   Hausman, Diana F ^c   Kurzrock, Razelle ^a   Jimeno, Antonio ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c Oncothyreon Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BREAST CANCER; CARCINOMA; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GENE; HUMAN; HYPERTENSION; KRAS GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; DIARRHEA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FATIGUE; FEMALE; GONANES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MUTATION; NAUSEA; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; TREATMENT OUTCOME; VOMITING;

EID: 84864493357     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0714     Document Type: Article

References (41)

1. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-95. (Pubitemid 34214843)
2. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-45. (Pubitemid 46328463)
3. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-31.
4. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102. (Pubitemid 29036292)
5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
6. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006;118:1877-83.
7. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82. (Pubitemid 43740454)
8. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
9. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
10. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875-8. (Pubitemid 40525186)
11. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitor. Mol Cancer Ther 2011;10:558-65.
12. Miyake T, Yoshino K, Enomoto T, Takata T, Ugaki H, Kim A, et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett 2008;261:120-6.
13. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;12:5932-5. (Pubitemid 44703751)
14. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-5. (Pubitemid 29190320)
15. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-41.
16. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
17. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 2007;101:249-57. (Pubitemid 46169878)
18. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998;16:2879-83. (Pubitemid 28383272)
19. Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 2011;20:507-18.
20. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
21. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
22. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009;16:463-74.
23. Sun CY, Hu Y, Huang J, Chu ZB, Zhang L, She XM, et al. Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol 2010;31:121-8.
24. Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, et al. Synthesis and biological evaluation of synthetic viridins derived fromC (20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org Biomol Chem 2004;2:1911-20.
25. Klucher K, Vo A, Walker C, Rosler R, Taylor J, Millard J, et al. 17-Hydroxy-PX-866, the primary metabolite of PX-866, an irreversible, pan-isoform inhibitor of phosphatidylinositol-3 (PI3) kinase, has increased activity in biochemical and cellular assays [abstract]. In: AACR Special Conference on Targeting PI3K/mTOR Signaling in Cancer; 2011 Feb 24-27. Seattle, WA: Oncothyreon Inc.; 2011.
26. Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72. (Pubitemid 39193758)
27. Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SAG, et al. PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway. Mol Cell Biochem 2007;300:77-87. (Pubitemid 46881818)
28. Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4:1349-57.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
30. Shackelford W, Deng S, Murayama K, Wang J. A new technology for mutation detection. Ann N Y Acad Sci 2004;1022:257-62. (Pubitemid 38951612)
31. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90.
32. Besse B, Soria J,Gomez-Roca C, Ware A, Adjei A, Dy GK, et al.Aphase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29:2011 (suppl; abstr 3044).
33. Juric D, Rodon J, Gonzalez-Angulo A, Burris H, Bendell J, Berlin J, et al. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr CT-01. doi: 1538-7445. AM2012-CT-01.
34. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
35. Woenckhaus J, Steger K, Sturm K, Munstedt K, Franke FE, Fenic I. Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch 2007;450:387-95. (Pubitemid 46466383)
36. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, et al. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009;29:1739-43.
37. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
38. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 2011;17:3272-81.
39. Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, et al. PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity. Mol Cancer Ther 2011;10:2189-99.
40. Koul D, Fu J, Shen R, Lafortune TA, Wang S, Tiao N, et al. Antitumor activity of NVP-BKM120- a selective pan class 1 PI3 Kinase inhibitor showed differential forms of cell death based on P53 status of glioma cells. Clin Cancer Res 2012;18:184-95.
41. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, TsimberidouAM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.